BRIEF-Spectre Acquisition Corp Files For IPO Of Up To $60 Million

BRIEF-Spectre Acquisition Corp Files For IPO Of Up To $60 Million - SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Spectre Acquisition Corp Files For IPO Of Up To $60 Million - SEC Filing

Mar 10, 2026 10:46 PM

Dec 17 (Reuters) - Spectre Acquisition Corp:

* BLANK CHECK CO, SPECTRE ACQUISITION CORP FILES FOR IPO OF

UP TO

$60 MILLION - SEC FILING

* SPECTRE ACQUISITION CORP SAYS ARC GROUP SECURITIES LLC IS

UNDERWRITER TO IPO

* SPECTRE ACQUISITION CORP: PLAN TO APPLY FOR LISTING UNITS

NASDAQ, UNDER SYMBOL "SPEXU"

;))

Previous page： Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis Next page： --Archer-Daniels-Midland Compliance Chief Leaves Amid Accounting Probe, Bloomberg Reports

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis

Nov 13, 2024

On Wednesday, Aileron Therapeutics Inc ( ALRN ) revealed topline data from Cohort 2 of its Phase 1b trial of safety and tolerability of inhaled LTI-03 for idiopathic pulmonary fibrosis (IPF). LTI-03 is a novel, Caveolin-1-related peptide that modulates profibrotic activity and sustains critical alveolar epithelial cells. Following inhaled administration of high dose LTI-03 (5 mg BID), a positive trend was observed...

--Archer-Daniels-Midland Compliance Chief Leaves Amid Accounting Probe, Bloomberg Reports

Nov 13, 2024

01:14 PM EST, 11/13/2024 (MT Newswires) -- Price: 51.85, Change: +0.41, Percent Change: +0.81 ...

BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition

Nov 13, 2024

On Wednesday, BioNTech SE ( BNTX ) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on discovering and developing antibodies for oncological or inflammatory diseases. With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. Also Read: BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts...

Market Chatter: Meta to Launch Ads on Threads Platform in Early 2025

Nov 13, 2024

01:05 PM EST, 11/13/2024 (MT Newswires) -- Meta Platforms ( META ) plans to launch advertisements on its social media platform, Threads, in early 2025, The Information reported Wednesday, citing three people with direct knowledge of the matter. Meta didn't immediately respond to a request for comment from MT Newswires. (Market Chatter news is derived from conversations with market professionals...